Cambridge Major Laboratories & AAIPharma Services Announce New CEO


Cambridge Major Laboratories, Inc. and AAIPharma Services, Corp. recently announced
the appointment of Patrick D. Walsh as the Chief Executive Officer (CEO) of the merged
company.

“We are very excited to be working with Pat on the continued growth of CML and AAIPharma. He is a well-respected CEO with over 30 years of leadership experience in the pharmaceutical industry. AAIPharma’s industry-leading formulation development and analytical service offerings complement CML’s world-class API development and manufacturing capabilities, and the combination creates an industry-leading contract development and manufacturing organization (CDMO) that is positioned for significant growth and expansion,” said Kyle Bradford, American Capital Managing Director.

“The client response to our merger announcement has been very positive,” said Mr. Walsh. “Providing an integrated service offering, coupled with a stellar regulatory track record, allows the combined business to exceed the expectations of our global pharma client base.”

The combined company forms the premier global supplier of integrated CMC services, including process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid and sterile), packaging, and stability services.

AAIPharma Services Corp. is a leading provider of contract services that support all phases of drug development. The company’s wide array of capabilities includes analytical and formulation development, material testing services, microbiology, clinical and commercial contract manufacturing, pharmaceutical packaging, and stability services. For more information, visit www.aaipharma.com.

Cambridge Major Laboratories, Inc. (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The company produces pharmaceutical intermediates and APIs from early preclinical development
to commercial manufacturing. For more information, visit www.c-mlabs.com.